A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders ...

Family Heart Foundation unveiled the Cholesterol Connect program for LDL-C Awareness Day, aiming to make it easier for people ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

Hippocratic AI is developing a generative AI model that aims to help providers complete non-diagnostic and patient-facing ...